PDF(Pubmed)
Abstract：
UNASSIGNED: The Fibromyalgia Syndrome (FMS) is a multifaceted chronic pain disorder that exerts a substantial impact on the overall state of health and quality of life of patients.
UNASSIGNED: Investigate the effects of exercise therapy and adherence to the American College of Sports Medicine (ACSM) guidelines on treatment outcomes in FMS patients.
UNASSIGNED: The literature search, which concluded in October 2023, encompassed studies investigating the impact of exercise interventions on patients diagnosed with FMS and providing adequate data for calculating standardized mean difference (SMD). The primary outcome measures encompassed the Fibromyalgia Impact Questionnaire (FIQ) and Health Assessment Questionnaire (HAQ), while secondary outcome measures comprised pain levels, sleep quality, fatigue, and mental health.
UNASSIGNED: Among 4,008 records, 19 studies (patients = 857) were eligible for qualitative synthesis. The meta-analysis revealed that the SMD for overall state of health impact was -0.94 (95%CI -1.26, -0.63), and the pooled SMD for the subgroup with high adherence to ACSM guidelines was -1.17 (95%CI -1.65, -0.69). The SMD for the subgroup with low or uncertain adherence was -0.73 (95%CI -1.12, -0.34). The overall effects included a -1.21 (95%CI -1.62, -0.79) SMD for pain relief, with high adherence achieving a -1.32 (95%CI -2.00, -0.64) SMD and low adherence a -1.06 (95%CI -1.55, -0.57) SMD. Mental health improvements showed a -0.95 (95%CI -1.32, -0.57) overall SMD, with high and low adherence subgroups at -0.96 (95%CI -1.62, -0.30) and -0.94 (95%CI -1.29, -0.60), respectively. Sleep quality impact was -1.59 (95%CI -2.31, -0.87) overall, with high adherence at -1.71 (95%CI -2.58, -0.83) and low adherence at -1.11 (95%CI -1.88, -0.33). Fatigue impact had a -1.55 (95%CI -2.26, -0.85) overall SMD, with -1.77 (95%CI -3.18, -0.36) for high adherence and -1.35 (95%CI -2.03, -0.66) for low adherence.
UNASSIGNED: Exercise therapy can improve the overall state of health, pain, sleep, and fatigue of FMS patients, particularly when adhering to ACSM guidelines. However, adherence levels do not affect mental health gains, indicating a need for future research on psychological impact.
UNASSIGNED: https://inplasy.com/inplasy-2024-3-0106/, identifier INPLASY202430106.
UNASSIGNED: Investigate the effects of exercise therapy and adherence to the American College of Sports Medicine (ACSM) guidelines on treatment outcomes in FMS patients.
UNASSIGNED: The literature search, which concluded in October 2023, encompassed studies investigating the impact of exercise interventions on patients diagnosed with FMS and providing adequate data for calculating standardized mean difference (SMD). The primary outcome measures encompassed the Fibromyalgia Impact Questionnaire (FIQ) and Health Assessment Questionnaire (HAQ), while secondary outcome measures comprised pain levels, sleep quality, fatigue, and mental health.
UNASSIGNED: Among 4,008 records, 19 studies (patients = 857) were eligible for qualitative synthesis. The meta-analysis revealed that the SMD for overall state of health impact was -0.94 (95%CI -1.26, -0.63), and the pooled SMD for the subgroup with high adherence to ACSM guidelines was -1.17 (95%CI -1.65, -0.69). The SMD for the subgroup with low or uncertain adherence was -0.73 (95%CI -1.12, -0.34). The overall effects included a -1.21 (95%CI -1.62, -0.79) SMD for pain relief, with high adherence achieving a -1.32 (95%CI -2.00, -0.64) SMD and low adherence a -1.06 (95%CI -1.55, -0.57) SMD. Mental health improvements showed a -0.95 (95%CI -1.32, -0.57) overall SMD, with high and low adherence subgroups at -0.96 (95%CI -1.62, -0.30) and -0.94 (95%CI -1.29, -0.60), respectively. Sleep quality impact was -1.59 (95%CI -2.31, -0.87) overall, with high adherence at -1.71 (95%CI -2.58, -0.83) and low adherence at -1.11 (95%CI -1.88, -0.33). Fatigue impact had a -1.55 (95%CI -2.26, -0.85) overall SMD, with -1.77 (95%CI -3.18, -0.36) for high adherence and -1.35 (95%CI -2.03, -0.66) for low adherence.
UNASSIGNED: Exercise therapy can improve the overall state of health, pain, sleep, and fatigue of FMS patients, particularly when adhering to ACSM guidelines. However, adherence levels do not affect mental health gains, indicating a need for future research on psychological impact.
UNASSIGNED: https://inplasy.com/inplasy-2024-3-0106/, identifier INPLASY202430106.
摘要：
■纤维肌痛综合征（FMS）是一种多方面的慢性疼痛障碍，对患者的总体健康状况和生活质量产生重大影响。
■研究运动疗法和遵守美国运动医学学院（ACSM）指南对FMS患者治疗结果的影响。
■文献检索,这项研究于2023年10月结束,涵盖了调查运动干预对FMS患者的影响的研究,并为计算标准化平均差(SMD)提供了足够的数据.主要结果指标包括纤维肌痛影响问卷（FIQ）和健康评估问卷（HAQ）。而次要结果指标包括疼痛水平，睡眠质量,疲劳,和心理健康。
■在4,008条记录中，19项研究（患者=857）符合定性综合条件。荟萃分析显示，总体健康状况影响的SMD为-0.94（95CI-1.26，-0.63），ACSM指南依从性高的亚组的合并SMD为-1.17(95CI-1.65,-0.69).依从性低或不确定的亚组的SMD为-0.73（95CI-1.12，-0.34）。总体效果包括-1.21（95CI-1.62，-0.79）SMD用于缓解疼痛，高依从性达到-1.32（95CI-2.00，-0.64）SMD，低依从性达到-1.06（95CI-1.55，-0.57）SMD。心理健康改善显示整体SMD为-0.95（95CI-1.32，-0.57），高和低依从性亚组在-0.96（95CI-1.62，-0.30）和-0.94（95CI-1.29，-0.60），分别。睡眠质量总体影响为-1.59（95CI-2.31，-0.87），高依从性为-1.71（95CI-2.58，-0.83），低依从性为-1.11（95CI-1.88，-0.33）。疲劳冲击的整体SMD为-1.55（95CI-2.26，-0.85），高依从性为-1.77（95CI-3.18，-0.36），低依从性为-1.35（95CI-2.03，-0.66）。
■运动疗法可以改善整体健康状态，疼痛,睡眠,和FMS患者的疲劳，特别是在遵守ACSM准则时。然而,依从性水平不会影响心理健康的提高，这表明需要对心理影响进行未来的研究。
■https://inplasy.com/inplasy-2024-3-0106/,标识符INPLASY202430106。
■研究运动疗法和遵守美国运动医学学院（ACSM）指南对FMS患者治疗结果的影响。
■文献检索,这项研究于2023年10月结束,涵盖了调查运动干预对FMS患者的影响的研究,并为计算标准化平均差(SMD)提供了足够的数据.主要结果指标包括纤维肌痛影响问卷（FIQ）和健康评估问卷（HAQ）。而次要结果指标包括疼痛水平，睡眠质量,疲劳,和心理健康。
■在4,008条记录中，19项研究（患者=857）符合定性综合条件。荟萃分析显示，总体健康状况影响的SMD为-0.94（95CI-1.26，-0.63），ACSM指南依从性高的亚组的合并SMD为-1.17(95CI-1.65,-0.69).依从性低或不确定的亚组的SMD为-0.73（95CI-1.12，-0.34）。总体效果包括-1.21（95CI-1.62，-0.79）SMD用于缓解疼痛，高依从性达到-1.32（95CI-2.00，-0.64）SMD，低依从性达到-1.06（95CI-1.55，-0.57）SMD。心理健康改善显示整体SMD为-0.95（95CI-1.32，-0.57），高和低依从性亚组在-0.96（95CI-1.62，-0.30）和-0.94（95CI-1.29，-0.60），分别。睡眠质量总体影响为-1.59（95CI-2.31，-0.87），高依从性为-1.71（95CI-2.58，-0.83），低依从性为-1.11（95CI-1.88，-0.33）。疲劳冲击的整体SMD为-1.55（95CI-2.26，-0.85），高依从性为-1.77（95CI-3.18，-0.36），低依从性为-1.35（95CI-2.03，-0.66）。
■运动疗法可以改善整体健康状态，疼痛,睡眠,和FMS患者的疲劳，特别是在遵守ACSM准则时。然而,依从性水平不会影响心理健康的提高，这表明需要对心理影响进行未来的研究。
■https://inplasy.com/inplasy-2024-3-0106/,标识符INPLASY202430106。
